Leap Therapeutics (NASDAQ:LPTX) and UCB (OTCMKTS:UCBJF) Critical Survey

UCB (OTCMKTS:UCBJF) and Leap Therapeutics (NASDAQ:LPTX) are both medical companies, but which is the superior investment? We will compare the two companies based on the strength of their risk, institutional ownership, valuation, earnings, analyst recommendations, dividends and profitability.

Earnings and Valuation

This table compares UCB and Leap Therapeutics”s gross revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
UCB	$5.27 billion	10.23	$371.23 million	N/A	N/A
Leap Therapeutics	N/A	N/A	-$67.56 million	($1.22)	-1.68

UCB has higher revenue and earnings than Leap Therapeutics.

Volatility and Risk

UCB has a beta of 0.47, indicating that its share price is 53% less volatile than the S&P 500. Comparatively, Leap Therapeutics has a beta of -0.06, indicating that its share price is 106% less volatile than the S&P 500.

Profitability

This table compares UCB and Leap Therapeutics’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
UCB	N/A	N/A	N/A
Leap Therapeutics	N/A	-247.44%	-146.51%

Analyst Ratings

This is a breakdown of recent ratings and target prices for UCB and Leap Therapeutics, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
UCB	0	0	2	0	3.00
Leap Therapeutics	1	0	0	0	1.00

Insider & Institutional Ownership

30.5% of Leap Therapeutics shares are held by institutional investors. 4.3% of Leap Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Summary

UCB beats Leap Therapeutics on 7 of the 9 factors compared between the two stocks.

About UCB

UCB SA, a biopharmaceutical company, develops products and solutions for people with neurology and immunology diseases worldwide. The company's primary products include Cimzia for inflammatory TNF mediated diseases, as well as ankylosing spondylitis, axial spondyloarthritis, Crohn's disease, non-radiographic axial spondyloarthritis, plaque psoriasis, psoriatic arthritis, and rheumatoid arthritis; Vimpat, Keppra, and Briviact for epilepsy; Neupro for Parkinson's disease and restless legs syndrome; Nayzilam, a nasal spray rescue treatment for epilepsy seizure clusters; and Zyrtec and Xyzal for allergies. It also offers Evenity for the treatment of osteoporosis in postmenopausal women; Bimzelx for treating plaque psoriasis, psoriatic arthritis, and axial spondyloarthritis; and Fintepla to treat Dravet syndrome. In addition, the company is involved in developing rozanolixizumab and Zilbrisq to treat myasthenia gravis; dapirolizumab pegol for systemic lupus erythematosus; fenfluramine to treat CDKL5 deficiency disorder; doxecitine for TK2 deficiency disorder; STACCATO alprazolam for stereotypical prolonged seizures; bepranemab to treat Alzheimer's disease; minzasolmin and UCB0222 for Parkinson's disease; and UCB1381 and UCB9741 for atropic dermatitis. Further, it engages in contract manufacturing activities. UCB SA has collaboration agreements with Amgen, Biogen, Roche/Genentech, Novartis, and Otsuka. The company was incorporated in 1925 and is headquartered in Brussels, Belgium.

About Leap Therapeutics

Leap Therapeutics, Inc., a biopharmaceutical company, acquires and develops therapies for the treatment of cancer. Its lead clinical stage programs include DKN-01, a monoclonal antibody that inhibits Dickkopf-related protein 1, which is in multiple ongoing clinical trials for treating esophagogastric, hepatobiliary, gynecologic, and prostate cancers. Leap Therapeutics, Inc. has an option and license agreement with BeiGene, Ltd. to develop and commercialize DKN-01 in Asia (excluding Japan), Australia, and New Zealand. The company was formerly known as HealthCare Pharmaceuticals, Inc. and changed its name to Leap Therapeutics, Inc. in November 2015. Leap Therapeutics, Inc. was incorporated in 2011 and is based in Cambridge, Massachusetts.